You are here

Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis

Last updated on November 15, 2019

FOR MORE INFORMATION
Study Location
Mexico City, D.f., Mexico
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female >18 years of age at time of enrollment

- Clinical diagnosis of stable plaque type psoriasis

- Two target plaques of similar severity meeting the following criteria:

- 5 cm2 and ≤ 100 cm2, computed by multiplying the greatest diameter of the plaque
by the diameter of the plaque perpendicular to the greatest diameter Bilaterally
located (right/left) plaques on the arms or plaques located on the trunk. Plaques
located on the trunk must be separated by at least 10 cm Overall target plaque
severity score (OTPSS) of 2-4 (mild to moderate) with no more than a 1 point
difference in the scores of the two target plaques

- Willing and able to apply study drug as directed, comply with study instructions and
commit to all follow-up visits

- Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior
to initiation of any protocol related procedures

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any dermatological conditions, disease state or physical condition that could
interfere with clinical evaluations or might expose the patient to an unacceptable
risk by study participation

- Any underlying disease(s) or other dermatological conditions that require the use of
exclusionary topical or systemic therapy (see below)

- Clinically significant, abnormal Screening laboratory results (unless approved by the
medical monitor)

- Known sensitivity to any of the components of the study medication

- Spontaneously improving or rapidly deteriorating psoriatic plaques or
pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis

- Concomitant use of topical or systemic therapies that might alter the course of
psoriasis

- Females of child bearing potential. Females must be post-menopausal (based on FSH
levels) or surgically sterile (hysterectomy or bilateral oophorectomy)

- Washout periods for exclusionary therapies:

Oral retinoids: 8 weeks Non-retinoid systemic drugs that might alter the course of
psoriasis: 4 weeks Psoralens with UV-A (PUVA): 4 weeks Ultraviolet-B (UVB) therapy: 4 weeks
Topical drugs that might alter the course of psoriasis: 2 weeks Use of
emollients/moisturizers on area(s) to be treated: 2 days prior to Baseline visit

- AIDS or AIDS-related illness

- Concurrent participation in another drug or device research study or within 30 days
prior to enrollment

- Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)

- Use of a beta-blocking medication (e.g., Propranolol) if the dose has not been
stabilized for at least 3 months

- Use of AN2728 in a previous clinical trial

NCT01029405
Pfizer
Completed
Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis
NCT03885089
All Genders
0+
Years
Tokyo,
Descriptive Information
Brief Title  ICMJE Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis
Official Title  ICMJE A Double-Blind,Randomized, 12 Week, Bilateral Study of the Safety and Efficacy of AN2728 Ointment B, 2% and 0.5%, Versus Ointment B Vehicle in the Treatment of Patients With Plaque Type Psoriasis
Brief SummaryThe purpose of this study is to evaluate the safety and efficacy of AN2728 Ointment B, 2.0% and 0.5%, compared to Ointment Vehicle B, applied once or twice daily for 12 weeks, in the treatment of plaque type psoriasis
Detailed DescriptionThis is a multicenter, randomized, double-blind, vehicle-controlled, bilateral design. Patients will apply both test article AN2728 Ointment B (0.5% or 2%), and Ointment B Vehicle twice daily for 12 weeks. The assigned study medication will be applied to two comparable treatment targeted plaques identified at baseline. One test article will be applied to one plaque and the other test article to an anatomically distinct plaque. All efficacy evaluations will be measured from only the two plaques identified at the baseline visit.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Psoriasis
Intervention  ICMJE
  • Drug: AN2728
    Ointment B, 2% or 0.5% applied once or twice daily
  • Drug: Placebo
    Ointment B Vehicle applied once or twice daily
Study Arms  ICMJE
  • Active Comparator: 1. AN2728 Ointment B
    2%, administered twice daily
    Intervention: Drug: AN2728
  • Placebo Comparator: 2. AN2728 Ointment B Vehicle
    Intervention: Drug: Placebo
  • Active Comparator: 3. AN2728 Ointment B
    2%, administered once daily
    Intervention: Drug: AN2728
  • Active Comparator: 4. AN2728 Ointment B
    0.5%, administered twice daily
    Intervention: Drug: AN2728
  • Active Comparator: 5. AN2728 Ointment B
    0.5%, administered once daily
    Intervention: Drug: AN2728
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: June 22, 2010)
145
Original Estimated Enrollment  ICMJE
 (submitted: December 8, 2009)
140
Actual Study Completion Date  ICMJE June 2010
Actual Primary Completion DateMay 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female >18 years of age at time of enrollment
  • Clinical diagnosis of stable plaque type psoriasis
  • Two target plaques of similar severity meeting the following criteria:

    • 5 cm2 and ? 100 cm2, computed by multiplying the greatest diameter of the plaque by the diameter of the plaque perpendicular to the greatest diameter Bilaterally located (right/left) plaques on the arms or plaques located on the trunk. Plaques located on the trunk must be separated by at least 10 cm Overall target plaque severity score (OTPSS) of 2-4 (mild to moderate) with no more than a 1 point difference in the scores of the two target plaques
  • Willing and able to apply study drug as directed, comply with study instructions and commit to all follow-up visits
  • Ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol related procedures

Exclusion Criteria:

  • Any dermatological conditions, disease state or physical condition that could interfere with clinical evaluations or might expose the patient to an unacceptable risk by study participation
  • Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see below)
  • Clinically significant, abnormal Screening laboratory results (unless approved by the medical monitor)
  • Known sensitivity to any of the components of the study medication
  • Spontaneously improving or rapidly deteriorating psoriatic plaques or pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis
  • Concomitant use of topical or systemic therapies that might alter the course of psoriasis
  • Females of child bearing potential. Females must be post-menopausal (based on FSH levels) or surgically sterile (hysterectomy or bilateral oophorectomy)
  • Washout periods for exclusionary therapies:

Oral retinoids: 8 weeks Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks Psoralens with UV-A (PUVA): 4 weeks Ultraviolet-B (UVB) therapy: 4 weeks Topical drugs that might alter the course of psoriasis: 2 weeks Use of emollients/moisturizers on area(s) to be treated: 2 days prior to Baseline visit

  • AIDS or AIDS-related illness
  • Concurrent participation in another drug or device research study or within 30 days prior to enrollment
  • Use of lithium- or hydroxychloroquine-containing products (e.g., Plaquenil)
  • Use of a beta-blocking medication (e.g., Propranolol) if the dose has not been stabilized for at least 3 months
  • Use of AN2728 in a previous clinical trial
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Mexico
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01029405
Other Study ID Numbers  ICMJE AN2728-PSR-203
C3291016 ( Other Identifier: Pfizer )
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateJanuary 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now